MedTrace Logo

Standard Versus Mini Percutaneous Nephrolithotomy for Renal Stones

NCT07464717 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2026-03-11

No results posted yet for this study

Summary

Renal stone disease is a common urological condition associated with significant morbidity. Percutaneous nephrolithotomy (PCNL) is the standard treatment for renal stones larger than 2 cm. Although standard PCNL (Percutaneous nephrolithotomy) is associated with high stone-free rates, it carries a risk of complications such as bleeding and prolonged hospital stay. Mini percutaneous nephrolithotomy has been introduced as a less invasive alternative with the potential to reduce morbidity. However, evidence comparing outcomes between mini-PCNL (Percutaneous nephrolithotomy) and standard PCNL (Percutaneous nephrolithotomy) remains inconsistent, particularly in the local population. This randomized controlled trial aims to compare operative and postoperative outcomes of mini-PCNL versus standard PCNL in patients with renal stones.

Conditions

  • Renal Stones

Interventions

PROCEDURE

Mini Percutaneous Nephrolithotomy

Mini-PCNL (Percutaneous nephrolithotomy) performed under general anesthesia using small-caliber tract dilation and Pneumatic lithotripsy.

PROCEDURE

Standard Percutaneous Nephrolithotomy

Standard PCNL performed under general anesthesia using conventional tract dilation and Nephroscope-assisted stone removal.

Sponsors & Collaborators

  • Khyber Teaching Hospital

    lead OTHER

Principal Investigators

  • Dr Hazrat Ullah, MBBS, FCPS · Khyber Teaching Hospital Peshawar

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
60 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-08-16
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Pakistan

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07464717 on ClinicalTrials.gov